DelveInsight’s Diffuse Cutaneous Systemic Sclerosis Market Insights report includes a comprehensive understanding of current treatment practices, emerging diffuse cutaneous systemic sclerosis drugs, ...

Please provide your email address to receive an email when new articles are posted on . The classically defined diffuse subtype of juvenile systemic sclerosis demonstrates more globally severe disease ...

(HealthDay News) – Patients with diffuse systemic sclerosis (SSc), without any clinical evidence of cardiovascular disease, have indicators of subclinical atherosclerosis. To identify signs of early ...

AMSTERDAM — For patients with diffuse cutaneous systemic sclerosis, an autoimmune disease for which there are few treatment options, lenabasum (JBT-101, Corbus Pharmaceuticals) shows potential, new ...

Please provide your email address to receive an email when new articles are posted on . Patients showed no difference in skin fibrosis whether they were given low-dose oral glucocorticoids or not. One ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The ...

Results reported for Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis. Company plans to meet with the FDA to ...

LISBON, Portugal — For most people with systemic sclerosis, adverse effects on the lungs, heart, skin, and other systems develop early and quickly, a large-scale, longitudinal study has confirmed for ...

BOSTON & LOUISVILLE, Ky.--(BUSINESS WIRE)--Talaris Therapeutics, Inc., a privately held biotechnology company developing transformative cell therapies that have the potential to induce durable immune ...

In an analysis of systemic sclerosis patients enrolled in an Australian cohort study, those who would have been eligible for ASCT in either of two clinical trials but were treated with now-standard ...

(MENAFN- GlobeNewsWire - Nasdaq) The diffuse cutaneous systemic sclerosis market landscape is evolving from conventional symptom-focused strategies toward therapies that specifically target fibrosis ...

New York, USA, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Diffuse Cutaneous Systemic Sclerosis Market Forecast: Opportunities and Growth Trends Upto 2034 | DelveInsight The diffuse cutaneous systemic sclerosis ...